Impact Factor
3.45
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.10
629 total citations
h5-index
28
h5 depth signal
Cited share
75.9%
164 of 216
Total citations
629
Citation footprint
Metric signal
2.57
External metric anchor
Self-citation
2.7%
17 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
425
Italy
201
Spain
87
China
86
United Kingdom
78
Citing Fields of Research
Hematology
859
Lymphomas
324
Immunology
93
Oncology
70
Metal Homeostasis
39
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,812
Articles tracked across the journal lifetime
Indexed publication set
216
164 cited publications
Last 12 months
123
10.3 publications/month
Open access share
23.6%
29 OA publications in the last year
Leading citing country
United States
425 citing publications
Leading citing field
Hematology
859 citing publications
Latest tracked publication
15 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Oct. 2008-
v1n1, Oct. 2008-
Research Focus & Classification
Indexed Subjects
Hematology
Broad Categories
Hematology
MeSH Descriptors
Hematologic Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/17474086.2026.2748721
Open DOI
Bibliometric analysis of the research trends of thalassemia in the past decade
02
03
DOI 10.1080/17474086.2026.2744003
Open DOI
Reframing sickle cell disease care: improving care with an embedded primary care model for chronic comorbidity management
04
DOI 10.1080/17474086.2026.2740886
Open DOI
Rising myeloproliferative neoplasms in younger patients: preserving future fertility and pregnancies
1. Myeloproliferative neoplasms (MPN) – encompassing essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) – are clonal hematopoietic stem cell disorders characterized by t...
05
DOI 10.1080/17474086.2026.2732994
Open DOI
Resistance mechanisms and therapeutic strategies after menin inhibitor failure in acute myeloid leukemia
1. Acute myeloid leukemia (AML) remains a biologically heterogeneous and clinically aggressive hematologic malignancy characterized by high relapse rates and poor long-term survival, particularly a...
06
DOI 10.1080/17474086.2026.2732995
Open DOI
Adaptations in pacritinib usage for myelofibrosis and thrombocytopenia since FDA approval
1. Myelofibrosis (MF) is driven by hyperactivation of the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway, resulting in progressive bone marrow fibrosis, extramedul...
07
DOI 10.1080/17474086.2026.2732981
Open DOI
Managing thrombotic risk in myeloproliferative disorders
1. Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by dysregulated myeloid proliferation. They comprise of polycythemia vera (PV), essential thrombocy...
08
09
DOI 10.1080/17474086.2026.2720126
Open DOI
Treatment of older adults with newly diagnosed FLT3 -mutated AML: focus on lower-intensity triplet regimens
1. FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase expressed on hematopoietic stem cells that plays a crucial role in their survival, proliferation, and differentiation, thereby sup...
10
DOI 10.1080/17474086.2026.2721482
Open DOI
Shear wave elastography as a screening modality for liver fibrosis in a comprehensive sickle cell disease clinic
1. Patients with sickle cell disease (SCD) are at risk of both acute and chronic liver injury due to multiple mechanisms, including microvascular ischemia from intrahepatic sickling, hemolysis-asso...
Bibliographical & Catalog Notes
Description based on first issue; title from cover.
Also issued online.